Trial · NCT07879677
A Virtual Reality Program for Nursing Home Residents With Physical Disabilities
NCT07879677, Not applicable, Not yet recruiting, Tung Wah College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Virtual Reality Program for Nursing Home Residents With Physical Disabilities. Trials, record NCT07879677. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879677
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Virtual Reality Program for Nursing Home Residents With Physical Disabilities
- NCT number
- NCT07879677
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Tung Wah College
- Conditions
- Older Adults Institutionalized in Residential Homes
- Interventions
- Psychological intervention
- First posted
- 2026-10-19
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Depression (PHD-9) | From enrollment to the end of intervention and three-month follow-up | Depression will be measured by Patient Health Questionnaire-9 (PHD-9). Total scores range from 0 to 27, where higher scores mean more severe depressive symptoms. |
| Primary | Anxiety (GAD-7) | From enrollment to the end of intervention and three-month follow-up | Anxiety will be measured by the Generalized Anxiety Disorder-7 (GAD-7). Total scores range from 0 to 21, where higher scores mean more severe anxiety symptoms. |
| Secondary | Well-being (WHO-5) | From enrolment to the end of intervention and three-month follow-up | Well-being will be measured by the World Health Organization-Five Well-Being Index (WHO-5). Total scores range from 0 to 100, where higher scores mean better subjective well-being and higher quality of life. |
| Secondary | Curiosity (ECS) | From enrolment to the end of intervention and three-month follow-up | Curiosity will be measured by the Epistemic Curiosity Scale (ECS). Total scores range from 10 to 40, where higher scores mean a stronger desire to explore new ideas and acquire new knowledge. |
| Secondary | Loneliness (6-item short DJGLS) | From enrolment to the end of intervention and three-month follow-up | Loneliness will be measured by the 6-Item Short De Jong Gierveld Loneliness Scale. Total scores range from 0 to 6, where higher scores mean more severe feelings of loneliness. |
| Secondary | Reminiscence (TALE) | From enrolment to the end of intervention and three-month follow-up | Reminiscence will be measured by the Thinking About Life Experiences (TALE) Scale. Total scores range from 15 to 75, where higher scores mean a greater frequency of using autobiographical memories to fulfill life functions. |
| Secondary | Quality of Life (EQ-5D-5L) | From enrolment to the end of intervention and three-month follow-up | Quality of Life will be measured by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). Health states are expressed as a 5-digit code, where "11111" indicates perfect health across all dimensions and "55555" indicates the worst possible health state. |
| Secondary | Perceived Social Support (PSSS) | From enrolment to the end of intervention and three-month follow-up | Perceived social support will be measured by the Perceived Social Support Scale (PSSS). Total scores range from 12 to 84, where higher scores mean a higher level of the individual's perception of social support. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879677
GET https://conductscience.org/api/trials/v1/NCT07879677/registered